Controversies Regarding Subclinical Leaflet Thrombosis After TAVR

Published: 25 February 2021

  • Views:

    Views Icon 788
  • Likes:

    Heart Icon 7

Overview

Full programme

Overview

A substantial number of patients develop a subclinical leaflet thrombosis (SLT) after transcatheter aortic valve replacement (TAVR).

The thrombus forms on the leaflets, which can lead to valve dysfunction and possibly to early valve degeneration. Multidetector computed tomography is the most sensitive imaging technique at detecting SLT.

Patients on antiplatelet drugs are at higher risk to develop SLT as compared to those on anticoagulants. During the live debate, the experts in the field will discuss controversies concerning SLT, including the routine use of oral anticoagulants and CT exams after TAVR.

Learning Objectives

  • To learn about the natural history, incidence and clinical implications of SLT
  • To learn about the mechanisms that may lead to SLT
  • To understand the diagnostic criteria SLT
  • To discuss the prevention and treatment options for SLT

Audience

  • Interventional cardiologists with focus on TAVR procedures
  • Cardiac Imaging specialists (Echocardiography, Computer Tomography)
  • General cardiologists
  • Specialists interested in management of antithrombotic therapies after TAVR

More from this programme

Part 1

Subclinical leaflet thrombosis after TAVR: Numbers and facts

Part 2

Debate: Patients should receive routine CT screening after TAVR to exclude subclinical valve thrombosis

Part 3

Debate: Patients should be routinely discharged on oral anticoagulants for prevention of subclinical valve thrombosis after TAVR

Faculty Biographies

Mamas A Mamas

Mamas A Mamas

Professor of Cardiology

Professor Mamas Mamas trained in Medicine at the University of Oxford, completing his clinical training in 2000. He is a Professor of Cardiology at Keele University and is a practicing interventional cardiologist.

Professor Mamas is an Associate Editor of Circulation Cardiovascular Interventions and a board member of the European Association of Percutaneous Cardiovascular Interventions, European Society of Cardiology. He is the Clinical Director of the Centre for Prognosis Research at Keele University, and leads a group of clinicians, data scientists and statisticians whose research interests focus around the use of routinely collected electronic healthcare data to inform the diagnosis, treatment and clinical outcomes of real-world patients with cardiovascular disease. He has published over 500 peer-reviewed manuscripts using big data in populations with cardiovascular disease.

Professor Mamas Mamas is an Editorial Board…

View full profile